Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection

Clin Pharmacol Ther. 2010 Nov;88(5):708-11. doi: 10.1038/clpt.2010.185. Epub 2010 Sep 29.

Abstract

As more pharmacogenomic insights into diseases and their treatments and toxicities are published each year, the challenge arises to incorporate such insights into clinical practice and drug development. For instance, recent genomic discoveries related to hepatitis C offer a challenge to clinicians, researchers,and health administrators to translate this information into knowledge in order to develop safer and more effective therapeutic strategies for all patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / chemistry
  • Antiviral Agents / therapeutic use*
  • Drug Administration Schedule
  • Drug Discovery*
  • Genotype
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics
  • Hepatitis C, Chronic / immunology
  • Humans
  • Interferons
  • Interleukins / genetics*
  • Phenotype
  • Polymorphism, Single Nucleotide*
  • Translational Medical Research

Substances

  • Antiviral Agents
  • IFNL3 protein, human
  • Interleukins
  • Interferons